As a leading provider of innovative elastomer materials with an ever-growing global footprint, Audia Elastomers designs our materials to look better…perform better…be better than traditional TPE, TPV, TPU, or TPEE. Let us develop something just for you or choose from one of the many grades currently available. And rest assured that throughout the process, you can count on our commitment to world-class service and quality that you’ll rarely find with other elastomer partners.

Elementis is a global specialty chemical company, with 1,300 employees operating 17 manufacturing sites across the globe. At Elementis, we bring a distinctive combination of expertise, innovation, and teamwork to every formulation challenge. We create high-value specialty additives that enhance the performance of our customers' products and make a positive change in the world. Combining our leading positions in the science of materials flow, surface modification, and formulation with access to unique natural materials, Elementis delivers unique chemistry, sustainable solutions to customers in a wide range of markets, including cosmetics, anti-perspirants, decorative and industrial coatings, automotive and ceramics. In 2022 Elementis reported revenue of $736m and adjusted operating profit of $101m.

We clean with Red and Yellow. Your payoff is in green! Our family has been manufacturing spectacular cleaning products since the 1930s. With a plant located in McKeesport, Pennsylvania, just outside of Pittsburgh, we cut our teeth scrubbing up the local steel mills. If your product didn’t perform as declared in the mills, you were physically removed from the premises. We quickly got the point. In the early 1970s the steel mills started to go away. To survive, we launched a nationwide campaign to provide simple programs for multi-unit retailers to clean their stores. We introduced product color-coding for simplicity. But foremost, just like the “mill days”, we hung our hats on making products that worked better. Our new customers took us to Europe and Canada where we developed our no-trade-secrets disclosure and environmentally friendly policies. Keep in mind, this was before the Right-to-Know Law and biodegradability concerns that appeared in the 1980s. Today, our products safely blast through grime in convenience stores, movie theatres, school districts, government locations, and steel mills. Yes, the mills are back! We know of no other company anywhere that produces products that are this safe, this environmentally responsible, and work this well. I would like to personally thank every customer from the steel mills to the convenience store industry for leading us down the path of quality. Scott Apter President

Hired as inaugural CFO to engage with investor community and maximize opportunities to finance new clinical trials for company’s core therapeutic, CT1812. Completed IPO in 2021 raising $52 million (NASDAQ: CGTX). Developed robust financial governance, best-practices, and protocols related to investor relations, financing, and capital allocation to optimize resources and accurately monitor spend across the organization. ►Identified full range of financing options and led equity fundraising and debt raising activities to position company for continued growth. ►Developed financial models and led business analysis of operating costs, net present value, product pricing, and market opportunity to forecast resource allocation throughout the preclinical to clinical to launch lifecycle. ►Created the company investment thesis leveraged in discussions with investors and bankers and articulated competitive positioning in the market. Ensured strong due diligence and tight financial controls were in place to support value proposition. ►Introduced executive compensation and equity plans aligned with company KPIs and strategy. Lead IT and HR functions. ►Oversee technology function and ensure risk mitigation and protocols for cybersecurity.

Arieca is leading the commercialization of easy to deploy liquid metal embedded elastomer (LMEE) technologies, which enable unprecedented performance in applications across semiconductor, aerospace, automotive, and healthcare industries. Our TIMbber product line targets leading semiconductor thermal interface material (TIM) challenges. Our Thubber® product line is developing solutions for future stretchable display and medical applications.

After a few false starts, my company is non-revenue producing at this point.

NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase’s pipeline includes therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington's disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.”